Skip to main content
. 2022 Aug 26;42(7):1897–1911. doi: 10.1148/rg.220045

Figure 14.

Type 2 axillary lymph node in a 32-year-old woman who underwent neoadjuvant chemotherapy and left mastectomy for invasive ductal carcinoma in 2019 and who presented for restaging with PET/CT. Seven days earlier, she received the first dose of the Pfizer BioNTech SARS-CoV-2 vaccine in the right arm. (A, B) Axial PET/CT images show mild to moderate FDG activity associated with right axillary nodes (arrow in A), new from 4 months earlier (arrow in B). (C) US image of the right axilla 2 months later shows a type 2 axillary lymph node (arrow) (BI-RADS 2).

Type 2 axillary lymph node in a 32-year-old woman who underwent neoadjuvant chemotherapy and left mastectomy for invasive ductal carcinoma in 2019 and who presented for restaging with PET/CT. Seven days earlier, she received the first dose of the Pfizer BioNTech SARS-CoV-2 vaccine in the right arm. (A, B) Axial PET/CT images show mild to moderate FDG activity associated with right axillary nodes (arrow in A), new from 4 months earlier (arrow in B). (C) US image of the right axilla 2 months later shows a type 2 axillary lymph node (arrow) (BI-RADS 2).